Cambridge Cancer Genomics
Cambridge
About Cambridge Cancer Genomics
Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment. Cambridge Cancer Genomics was founded on 2016 and is headquartered in Cambridge, England.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $8.5M
- Funding stage: M&A
- Last round: Seed (Dec 2018)
- Website: ccg.ai
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/cambridge-cancer-genomics-99789 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.